<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156558">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02125292</url>
  </required_header>
  <id_info>
    <org_study_id>SHP429-102</org_study_id>
    <nct_id>NCT02125292</nct_id>
  </id_info>
  <brief_title>Taste Assessment Study of SHP429 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, 3-period Crossover Taste Assessment Study to Characterize the Palatability of SHP429 When the Contents Are Sprinkled Onto Soft Foods or Emptied Into a Cup and Administered With Water in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the palatability of SHP429 capsule contents
      delivered via 3 means of administration (sprinkled on yogurt, sprinkled on applesauce, and
      emptied into a cup and administered with water).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Taste Assessment Questionnaire</measure>
    <time_frame>5 minutes post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Mesalamine (Vanilla Yogurt)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 500mg capsule contents sprinkled onto 1 tablespoon of low-fat vanilla yogurt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesalamine (Applesauce)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 500mg capsule contents sprinkled onto 1 tablespoon of applesauce</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesalamine (Dosing Cup)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 500mg capsule contents emptied into a dosing cup and taken with water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalamine</intervention_name>
    <arm_group_label>Mesalamine (Vanilla Yogurt)</arm_group_label>
    <arm_group_label>Mesalamine (Applesauce)</arm_group_label>
    <arm_group_label>Mesalamine (Dosing Cup)</arm_group_label>
    <other_name>Pentasa, SHP429</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  normal, healthy, adult male and female volunteers, without evidence of active or
             chronic disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth C Lasseter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology of Miami, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Call Center</last_name>
    <phone>1-866-842-5335</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kenneth C Lasseter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>April 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
